SG11201701077XA - Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives - Google Patents

Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives

Info

Publication number
SG11201701077XA
SG11201701077XA SG11201701077XA SG11201701077XA SG11201701077XA SG 11201701077X A SG11201701077X A SG 11201701077XA SG 11201701077X A SG11201701077X A SG 11201701077XA SG 11201701077X A SG11201701077X A SG 11201701077XA SG 11201701077X A SG11201701077X A SG 11201701077XA
Authority
SG
Singapore
Prior art keywords
preparing
synthetic intermediates
tetrahydroquinoline derivatives
derivatives
preparing synthetic
Prior art date
Application number
SG11201701077XA
Other languages
English (en)
Inventor
John Ford
Johannes Paulus Gerardus Seerden
Amandine Ledru
Original Assignee
Dezima Pharma B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51429345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201701077X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dezima Pharma B V filed Critical Dezima Pharma B V
Publication of SG11201701077XA publication Critical patent/SG11201701077XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
SG11201701077XA 2014-08-12 2015-07-29 Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives SG11201701077XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2014050556 2014-08-12
PCT/NL2015/050555 WO2016024858A1 (en) 2014-08-12 2015-07-29 Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives

Publications (1)

Publication Number Publication Date
SG11201701077XA true SG11201701077XA (en) 2017-03-30

Family

ID=51429345

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201701077XA SG11201701077XA (en) 2014-08-12 2015-07-29 Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives

Country Status (26)

Country Link
US (1) US10112904B2 (es)
EP (2) EP3180314B1 (es)
JP (1) JP6670310B2 (es)
KR (1) KR102572626B1 (es)
CN (1) CN107108558B (es)
AR (1) AR101509A1 (es)
AU (1) AU2015302407B2 (es)
BR (1) BR112017002873B1 (es)
CA (1) CA2958040C (es)
CL (1) CL2017000367A1 (es)
DK (1) DK3180314T3 (es)
EA (1) EA034357B1 (es)
ES (1) ES2926775T3 (es)
HR (1) HRP20221061T1 (es)
HU (1) HUE059947T2 (es)
IL (1) IL250525B (es)
LT (1) LT3180314T (es)
MA (1) MA40378B1 (es)
MX (1) MX367908B (es)
PL (1) PL3180314T3 (es)
PT (1) PT3180314T (es)
RS (1) RS63575B1 (es)
SG (1) SG11201701077XA (es)
SI (1) SI3180314T1 (es)
TW (1) TWI691490B (es)
WO (1) WO2016024858A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI4125911T3 (fi) 2021-03-05 2024-07-22 Newamsterdam Pharma B V Obisetrapibi dementioiden hoitoon
TW202310842A (zh) 2021-07-26 2023-03-16 荷蘭商新阿姆斯特丹製藥公司 高強度他汀弱反應物之治療
IL314031A (en) 2021-12-30 2024-09-01 Newamsterdam Pharma B V Materials and methods for improved phosphotransferases
US12006305B2 (en) * 2022-07-05 2024-06-11 Newamsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof
TW202416994A (zh) 2022-08-22 2024-05-01 荷蘭商新阿姆斯特丹製藥公司 固定劑量醫藥組合物及其用途
WO2024165395A1 (en) 2023-02-07 2024-08-15 Newamsterdam Pharma B.V. Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
CZ20032900A3 (cs) * 2001-04-30 2004-06-16 Pfizer Products Inc. Sloučeniny vhodné jako meziprodukty
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
CN101466679A (zh) * 2006-03-30 2009-06-24 田边三菱制药株式会社 制备四氢喹啉衍生物的方法

Also Published As

Publication number Publication date
TWI691490B (zh) 2020-04-21
BR112017002873A2 (pt) 2018-07-17
IL250525B (en) 2019-08-29
MA40378B1 (fr) 2022-10-31
DK3180314T3 (da) 2022-08-29
SI3180314T1 (sl) 2022-11-30
CN107108558B (zh) 2019-11-19
JP6670310B2 (ja) 2020-03-18
JP2017524742A (ja) 2017-08-31
BR112017002873A8 (pt) 2022-11-08
AU2015302407A1 (en) 2017-03-02
LT3180314T (lt) 2022-11-10
KR20170102204A (ko) 2017-09-08
MA40378A (fr) 2017-06-21
CA2958040C (en) 2022-09-13
KR102572626B1 (ko) 2023-08-30
EP4083022A1 (en) 2022-11-02
RS63575B1 (sr) 2022-10-31
EA201790364A1 (ru) 2017-07-31
MX2017001930A (es) 2018-03-01
PT3180314T (pt) 2022-09-02
BR112017002873B1 (pt) 2023-03-28
IL250525A0 (en) 2017-03-30
US10112904B2 (en) 2018-10-30
CL2017000367A1 (es) 2018-02-09
CN107108558A (zh) 2017-08-29
WO2016024858A1 (en) 2016-02-18
AR101509A1 (es) 2016-12-21
TW201613868A (en) 2016-04-16
EP3180314A1 (en) 2017-06-21
PL3180314T3 (pl) 2022-11-21
US20170267640A1 (en) 2017-09-21
HRP20221061T1 (hr) 2022-11-25
AU2015302407B2 (en) 2019-09-19
EP3180314B1 (en) 2022-06-22
ES2926775T3 (es) 2022-10-28
HUE059947T2 (hu) 2023-01-28
CA2958040A1 (en) 2016-02-18
MX367908B (es) 2019-09-11
EA034357B1 (ru) 2020-01-30

Similar Documents

Publication Publication Date Title
ZA201708142B (en) Process for preparing 4-amino-pyridazines
PL3325443T3 (pl) Sposób otrzymywania pridopidyny
IL252912A0 (en) Processes for preparing oxathiazine-like compounds
IL250525A0 (en) Process for the preparation of synthetic intermediates for the preparation of tetrahydroquinoline derivatives
PT3196196T (pt) Método para a preparação de calcobutrol
PL3295941T3 (pl) Sposób wytwarzania postaci a grapiprantu
IL248267B (en) A process for preparing converted cycloserines
SG11201606862VA (en) Process for preparing n-benzyl-3-hydroxy-4-substituted-pyridin-2-(1h)-ones
HK1245792A1 (zh) 製備α-甲酰胺吡咯烷衍生物的方法
IL253877A0 (en) Process for preparing 3-chloro-2-vinylphenylsulfonates
IL248565B (en) A process for the preparation of thiazole derivatives
IL243795A0 (en) A process for the preparation of a quinazoline derivative
GB201405359D0 (en) Synthetic process
IL249283B (en) Process for the preparation of 3-chloro-2-vinylphenol
PT3224226T (pt) Processo de preparação de eteno
IL241974A0 (en) Process for making erlotinib
ZA201701100B (en) Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives
PL3113919T3 (pl) Sposób powlekania fragmentu powierzchni
IL253630B (en) A process for the preparation of modified phenylisoxazoline derivatives
EP3233732B8 (en) Process for preparing monohydrogentrihalosilanes